# Quellis Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/quellis-biosciences

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.quellisbio.com
- Total disclosed funding: $17M
- Latest round: Series A (Dec 10, 2019)
- Investors on record: 2

## About

Based in Massachusetts, US and founded in 2017, Quellis Biosciences provides medicines for patients with life-threatening rare diseases and underserved by current treatment options. The company develops new monoclonal antibodies that help the immune system’s ability to fight off harmful antigens such as viruses. Quellis Biosciences raised funding from Perceptive Advisors in 2019 and was acquired by Catabasis Pharmaceuticals, Inc. in 2021.

The company works with pharmaceutical companies, by developing medicine with monoclonal antibodies for patients with rare diseases. Quellis Biosciences will offer their different developed therapies intended for a specific disease, pharmaceutical companies will then choose to manufacture and commercialized for public access.

## Funding rounds

- Series A, Dec 10, 2019, $17M — Perceptive Advisors, Viridian Therapeutics, Inc.

## Investors

- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series A
- Viridian Therapeutics, Inc. — Series A